This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): ARN-509, JNJ56021927, JNJ-927
Description: JNJ-56021927 is an androgen receptor antagonist that inhibits nuclear translocation and DNA binding of the receptor, thereby modulating expression of genes that drive prostate cancer growth.
Aragon and Johnson & Johnson
In June 2013, Aragon Pharmaceuticals announced a definitive agreement with Johnson & Johnson whereby Aragon will be acquired for $650 million in cash up front along with $350 million in contingent development milestone payments that could bring the total transaction value to $1 billion.
In August 2013, Johnson & Johnson announced it has successfully completed its acquisition of Aragon Pharmaceuticals.
Additional information available to subscribers only: